A Study to Assess Efficacy and Safety of Nasacort® Nasal Spray in Comparison With Flixonase® Nasal Spray in Adults Suffering From Perennial Allergic Rhinitis (PAR)

Inclusion criteria: * Females and males ≥18 and ≤50 years old. * Patients with previously diagnosed PAR with a positive skin prick test response to an appropriate allergen performed not earlier than 12 months prior to the Screening visit. * Patients must be clinically symptomatic (rTNSS reflecting symptoms for the previous 24 h ≥8 with two or more symptoms rated as moderate or severe). * Negative urine pregnancy test during screening before first dose of study medication is administered in women with child-bearing potential. * Women must use an effective contraceptive method during the study period. * Patients should be able to understand the study, including risks and adverse events; collaborating with Investigator and proceed according with protocol. * Signed informed consent form. Exclusion criteria: * Compromised ability to provide informed consent. * Participation in any other clinical study. * History of severe local reaction(s) or anaphylaxis to skin testing. * Upper respiratory tract or sinus infection that required antibiotic therapy without at least a 14-day washout prior to the Screening Visit, or viral upper respiratory infection within 2 weeks prior to the Screening Visit. * Subjects who have used any drug (Flixonase or Nasacort) in an investigational protocol 4 weeks prior to the Screening Visit. * Female subjects who are breast-feeding, pregnant, or intend to become pregnant. * Patients with nasal abnormalities, including nasal polyps, and marked septum devi…